MedTrace Logo

Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis

NCT01874340 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2015-06-01

Study results available
· View outcomes & findings →

Summary

To evaluate the efficacy and safety of AIN457 versus placebo in patients with relapsing multiple sclerosis.

Conditions

Interventions

DRUG

Placebo

Placebo will be administered at predefined visits over the 6-month treatment phase.

DRUG

AIN457

AIN457 will be administered at predefined visits over the 6-month treatment phase.

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2014-04-30
Completion
2014-04-30

Countries

  • Belgium
  • Czechia
  • France
  • Italy
  • Japan
  • Poland
  • Russia
  • Spain
  • Sweden
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01874340 on ClinicalTrials.gov